BioSpace News Archive

Companies forge relationship to accelerate peptide drug discovery for next-generation radiopharmaceuticals Pepscan brings proprietary world-leading peptide drug discovery expertise and technologies

Akari Therapeutics, Plc today announced that it has entered into definitive securities purchase agreements with certain accredited and institutional investors.

MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced new data from a study conducted by Eurofins Discovery (ERF.FP) Phenotypic Center of Excellence (“Eurofins”) comparing the biological activities of MyMD’s lead compound MYMD-1, with leading FDA approved TNF inhibitors (TNFi).

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has completed a successful End of phase II meeting with the US Food and Drug Administration (FDA).

Celularity Inc., the Brain Mapping Foundation and the Society for Brain Mapping and Therapeutics announced Robert J. Hariri, M.D., Ph.D., Founder, Chairman and Chief Executive Officer of Celularity, and Adjunct Professor of Neurosurgery at Weill Cornell College of Medicine, will be honored at the “Gathering for Cure Black Tie Awards Gala” during the SBMT Annual World Congress in Los Angeles on July 10, 2021.

The Cancer and Blood Specialty Clinic (CBSC) and Deep Lens announced today that they have entered into a strategic partnership to integrate artificial intelligence (AI)-based clinical trial matching solution, VIPER™, into the Southern California-based practice. VIPER uses proprietary, cloud-based technology to facilitate, triage and accelerate the clinical trial recruitment process.

Zebra Medical Vision, the leading medical imaging analytics company, announces an industry-first, landmark approval of a Category III Current Procedural Terminology (CPT) code application for utilizing AI for VCF detection as an incidental finding in chest CT, by the American Medical Association (AMA)

The biopsy devices market is anticipated to reach US$ 3,584.20 million by 2027 from US$ 2,230.86 million in 2019.

Bonafide, the women’s healthcare company offering naturally powerful solutions to manage menopause, today announces the release of its first State of Menopause Study, which aggregates the symptoms, treatments, and general dispositions of over 1,000 U.S. women in various stages of their menopause journey.

The laser therapy market is expected to reach US$ 3,514.02 million by 2027 from US$ 1,665.65 million in 2019; it is estimated to grow at a CAGR of 9.9% from 2020 to 2027.